2025-04-11 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Summary Statistics:**

* **Ticker:** MRK
* **Company:** Merck & Co Inc, a leading pharmaceutical company.
* **Cumulative Return (MRK):** 7.82%
* **Cumulative Return (VOO):** 61.97%
* **Return Difference (MRK vs VOO):** -54.1%
* **Relative Divergence:** 25.4% (indicating MRK's performance is in the lower 25th percentile relative to its historical performance compared to VOO).


**1. Performance Comparison:**

Merck & Co Inc (MRK) significantly underperformed the S&P 500 (VOO) over the analyzed period.  While VOO experienced a substantial cumulative return of 61.97%, MRK's return was only 7.82%, resulting in a large negative difference of -54.1%. The relative divergence of 25.4% indicates that this underperformance is relatively low compared to historical periods of divergence between the two.


**2. Alpha, Beta Analysis & Market Capitalization:**

The provided data shows inconsistent performance metrics for MRK across different periods. While CAGR (Compound Annual Growth Rate) fluctuates significantly, the maximum drawdown (MDD) remains relatively high consistently, except for during the years 2016-2018.  Alpha values suggest periods of outperformance (positive alpha) and underperformance (negative alpha) compared to the market. Beta values are high, indicating significant market sensitivity. The market capitalization shows substantial growth over the period.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 5.0% | 58.4% | -24.0% | 109.0 |
| 2016-2018  | 42.0% | 66.6% | 24.0% | 152.5 |
| 2017-2019  | 40.0% | 66.6% | 11.0% | 186.5 |
| 2018-2020  | 19.0% | 66.6% | -6.0% | 173.0 |
| 2019-2021  | -1.0% | 65.6% | -55.0% | 176.1 |
| 2020-2022  | 13.0% | 69.3% | 7.0% | 263.1 |
| 2021-2023  | 35.0% | 69.3% | 19.0% | 265.7 |
| 2022-2024  | -6.0% | 69.3% | -23.0% | 249.1 |
| 2023-2025  | -45.0% | 70.3% | -55.0% | 195.5 |


**3. Recent Price Movement:**

* **Last Price:** $77.33
* **Previous Close:** $81.91
* **5-day Moving Average:** $81.08
* **20-day Moving Average:** $88.65
* **60-day Moving Average:** $90.81

The stock price is significantly below all three moving averages, suggesting a downtrend.  The recent price change of -5.59 represents a notable drop.


**4. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4271 (Medium Risk)
* **RSI:** 10.86 (Extremely oversold; suggesting potential for a bounce but not necessarily a sustained uptrend)
* **PPO:** -1.59 (Negative value indicating bearish momentum)
* **Relative Divergence Change (20-day):** +8.6 (Short-term upward movement)
* **Expected Return:** -28.5% (Significant negative expected return over the long term compared to the S&P 500)

The extremely low RSI and negative PPO suggest a bearish trend.  However, the positive 20-day relative divergence change indicates some short-term upward pressure. The significant price drop of -5.59 reflects a likely market event impacting the price.


**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue        |
|------------|------|-----------------|
| 2024-11-06 | 1.25 | $16.66 B       |
| 2024-08-05 | 2.15 | $16.11 B       |
| 2024-05-03 | 1.88 | $15.78 B       |
| 2023-11-03 | 1.87 | $15.96 B       |
| 2024-11-06 | 1.87 | $15.96 B       |

There's a notable drop in EPS from Q2 2024 to Q3 2024. Revenue fluctuates within a relatively narrow range.  The repetition of the November 6th data point needs clarification.


**6. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |

Profit margins remain consistently high, although there's some fluctuation in revenue.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $46.31B    | 8.08%         |
| 2024-09-30 | $44.50B    | 7.09%         |
| 2024-06-30 | $43.58B    | 12.52%        |
| 2024-03-31 | $40.36B    | 11.80%        |
| 2023-12-31 | $37.58B    | -3.26%        |

Equity shows consistent growth, while ROE fluctuates but remains mostly positive, indicating generally good profitability.


**7. Overall Analysis:**

MRK significantly underperformed the S&P 500 over the analyzed period. While financial fundamentals show strong profitability and consistent revenue, the stock price is currently in a downtrend, suggesting a bearish sentiment.  The extremely low RSI suggests potential for a short-term bounce, but the negative PPO and significantly negative expected return, coupled with the significant underperformance relative to the market, paint a cautious outlook for the long term.  Further investigation into the reasons for the recent price drop and the Q3 2024 earnings decline is warranted before making any investment decisions. The high beta suggests that the stock is highly sensitive to market movements, making it a riskier investment.  Given the negative expected return and the current market conditions, caution is advised.
